Pacific Biosciences of California ... there remains a meaningful upgrade opportunity with approximately 125 active Sequel II and IIe users in the field, many of whom could transition to Revio ...

PacBio has been witnessing a positive estimate revision trend for 2023. Over the past 60 days, the Zacks Consensus Estimate for its adjusted loss per share has narrowed from $1.18 to $1.17.